Prothena Corporation plc (PRTA)

20,87 +0,31 (+1,51%) Al cierre: 04:00PM EDT

Prothena Corporation plc

77 Sir John Rogerson’s Quay
Block C Grand Canal Docklands
Dublin D02 VK60
Ireland
353 1 236 2500
https://www.prothena.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 173

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Gene G. Kinney Ph.D.	President, CEO & Director	1M	1,97M	1969
Mr. Tran B. Nguyen M.B.A.	CFO & Chief Strategy Officer	830,14k	5,92M	1974
Mr. Brandon S. Smith	Chief Operating Officer	757,79k	1,07M	1975
Ms. Carol D. Karp	Chief Regulatory Officer	701,48k	2,1M	1953
Dr. Hideki Garren M.D., Ph.D.	Chief Medical Officer	808,71k	1,09M	1965
Ms. Karin L. Walker CPA	Chief Accounting Officer & Controller	N/A	N/A	1963
Dr. Wagner M. Zago	Chief Scientific Officer	478,79k	N/A	1973
Mr. Mark C. Johnson C.F.A.	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Michael J. Malecek	Chief Legal Officer	588,25k	N/A	1966
Mr. David A. Ford	Chief People Officer	N/A	N/A	1970

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Gobierno corporativo

El ISS Governance QualityScore de Prothena Corporation plc, a día 1 de abril de 2024, es 4. Las puntuaciones base son Auditoría: 8; Tablero: 3; Derechos de los accionistas: 3; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.